Search research articles
Contact Us
Filters
Showing results (91-100 of 127) with videos related to
Page
of 13
Sort By:
Oncotarget
|
October 10, 2012
Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin
Jantine Posthumadeboer, Pim W van Egmond, Marco N Helder, et al.
BMC Cancer
|
May 22, 2013
IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma
Marieke L Kuijjer, Elisabeth F P Peterse, Brendy E W M van den Akker, et al.
British Journal of Cancer
|
March 27, 2018
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
Elisabeth F P Peterse, Bertine Niessen, Ruben D Addie, et al.
British Journal of Cancer
|
May 4, 2016
Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy
Marieke A de Graaff, Marije A J de Rooij, Brendy E W M van den Akker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2006
Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping
Rogier A Oldenburg, Karin Kroeze-Jansema, Hanne Meijers-Heijboer, et al.
Oncoimmunology
|
January 9, 2018
Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies
Marie Kostine, Inge H Briaire-de Bruijn, Arjen H G Cleven, et al.
Journal of Cellular and Molecular Medicine
|
March 27, 2009
Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix
Stefan M Willems, Alex B Mohseny, Crina Balog, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
September 13, 2016
Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line
Yvonne de Jong, Annemiek M van Maldegem, Adrian Marino-Enriquez, et al.
Genes, Chromosomes & Cancer
|
July 18, 2024
The Variable Genomic Landscape During Osteosarcoma Progression: Insights From a Longitudinal WGS Analysis
Debora M Meijer, Dina Ruano, Inge H Briaire-de Bruijn, et al.
Cancer Research
|
June 16, 2012
Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer
Kristiaan Lenos, Anna M Grawenda, Kirsten Lodder, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 127) with videos related to
Sort By:
Page
of 13
Oncotarget
|
October 10, 2012
Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin
Jantine Posthumadeboer, Pim W van Egmond, Marco N Helder, et al.
BMC Cancer
|
May 22, 2013
IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma
Marieke L Kuijjer, Elisabeth F P Peterse, Brendy E W M van den Akker, et al.
British Journal of Cancer
|
March 27, 2018
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
Elisabeth F P Peterse, Bertine Niessen, Ruben D Addie, et al.
British Journal of Cancer
|
May 4, 2016
Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy
Marieke A de Graaff, Marije A J de Rooij, Brendy E W M van den Akker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2006
Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping
Rogier A Oldenburg, Karin Kroeze-Jansema, Hanne Meijers-Heijboer, et al.
Oncoimmunology
|
January 9, 2018
Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies
Marie Kostine, Inge H Briaire-de Bruijn, Arjen H G Cleven, et al.
Journal of Cellular and Molecular Medicine
|
March 27, 2009
Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix
Stefan M Willems, Alex B Mohseny, Crina Balog, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
September 13, 2016
Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line
Yvonne de Jong, Annemiek M van Maldegem, Adrian Marino-Enriquez, et al.
Genes, Chromosomes & Cancer
|
July 18, 2024
The Variable Genomic Landscape During Osteosarcoma Progression: Insights From a Longitudinal WGS Analysis
Debora M Meijer, Dina Ruano, Inge H Briaire-de Bruijn, et al.
Cancer Research
|
June 16, 2012
Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer
Kristiaan Lenos, Anna M Grawenda, Kirsten Lodder, et al.
Page
of 13